<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="461">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04416048</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-PREVENT</org_study_id>
    <secondary_id>2020-002282-33</secondary_id>
    <nct_id>NCT04416048</nct_id>
  </id_info>
  <brief_title>Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19</brief_title>
  <acronym>COVID-PREVENT</acronym>
  <official_title>Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with moderate to severe COVID-19 present a very high risk of thromboembolic
      disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban
      compared with standard of care including low-molecular-weight heparin (LMWH) or
      unfractionated heparin (UFH) at prophylactic doses if applicable in the prevention of the
      composite of venous thromboembolism (deep vein thrombosis and/or fatal or non-fatal pulmonary
      embolism), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke,
      all-cause mortality or progression to intubation and invasive ventilation 35 days post
      randomization in patients with moderate to severe COVID-19.

      Experimental intervention/Index test:

      Patients randomized into the rivaroxaban arm will receive rivaroxaban 20 mg once daily (OD)
      until day 7 post randomization or hospital discharge, whichever occurs later, followed by a
      28-day-phase of prophylactic anticoagulation with rivaroxaban 10mg OD. Subjects with an eGFR
      between 30 and 50ml/min/1,73m2, will receive 15mg instead of 20mg OD.

      Control intervention/Reference test:

      The control group will receive standard of care including LMWH or UFH as thromboprophylaxis
      or no anticoagulation, if appropriate.

      Duration of intervention per patient:

      The total duration of the study treatment is flexible. For out-patients 7 days of therapeutic
      anticoagulation will be accompanied by 28 days-phase of prophylactic anticoagulation, summing
      up to 35 days. For subjects that require hospitalization, the duration of therapeutic
      anticoagulation will be at least 7 days or prolonged until discharge if hospitalized for more
      than 7 days post randomization.

      After discharge from the hospital the subject receives 28 days of thromboprophylaxis with
      rivaroxaban. No study medication will be given past day 60 post randomization. This adds up
      to a study duration between 35 and 60 days depending on the duration of the hospital stay.

      Follow-up per patient:

      The study has a follow-up of 60 days.

      Experimental and/or control off label or on label in Germany:

      Rivaroxaban has been approved for multiple indications worldwide. Over 100,000 subjects have
      been studied from Phase 1 through multiple large Phase 4 studies in multiple settings, e.g.
      for the reduction in the risk of stroke and systemic embolism in arterial fibrillation, deep
      vein thrombosis and pulmonary embolism, major cardiovascular events. The drug had not been
      studied in patients with COVID-19 as an anticoagulant agent, yet.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicenter, prospective, randomized, event-driven study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Central randomization will be implemented in this study. Subjects will be randomly assigned to 1 of 2 treatment groups based on a computer-generated randomization schedule prepared before the study under the supervision of the sponsor. The randomization will be stratified by site, gender, age, kidney function (subjects with eGFR ≥30 mL/min/1.73m2 and &lt;50 mL/min/1.73m2 versus subjects with eGFR ≥50 mL/min/1.73m2), history of CAD or heart failure and oxygen demand on admission to the hospital. The computer system will assign a unique treatment code, which will dictate the treatment assignment and study drug kits for the subject. The requestor must use his or her own user identification and personal identification number when contacting the system and will then give the relevant subject details to uniquely identify the subject.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause mortality or progression to intubation and invasive ventilation</measure>
    <time_frame>35 days post randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of disseminated intravascular coagulation (DIC) according to the ISTH criteria</measure>
    <time_frame>35 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days requiring invasive ventilation</measure>
    <time_frame>35 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days requiring non-invasive ventilation</measure>
    <time_frame>35 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement on a seven-category ordinal scale recommended by the WHO as clinical improvement scale for patients with respiratory infections</measure>
    <time_frame>35 days post randomization</time_frame>
    <description>scale range from 1 to 7; improvement means a reduction in the scale number of at least one point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment with rivaroxaban. (for more information see intervention description)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive standard of care (SOC) treatment SOC including prophylactic LMWH or UFH, when considered appropriate according to the judgment of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and &lt;50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>XARELTO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Of Care (SOC)</intervention_name>
    <description>Standard of care treatment</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be willing, understanding and able to provide written informed consent

          -  Subject must be a man or a woman with age &gt; 18 years at screening

          -  Subject must have an active moderate to severe COVID-19 confirmed by

             o A positive SARS-CoV-2 PCR test in the last 14 days

          -  At least one of the following features should be present

               -  D-Dimer elevation &gt; 1.5 ULN (age adjusted cut-offs) AND/OR

               -  Cardiac injury reflected by an elevation in hs-cTnT &gt; 2.0 upper limit of normal
                  (ULN) AND at least one of the following conditions:

                    -  Known coronary artery disease (CAD)

                    -  Known diabetes mellitus

                    -  Active smoking

          -  A woman of childbearing potential must have a negative serum or urine pregnancy test
             before randomization occurs. Before randomization, a woman must be either:

               -  Postmenopausal, defined as &gt;45 years of age with amenorrhea for at least 18
                  months,

               -  If menstruating:

                    -  If heterosexually active, practicing a highly effective method of birth
                       control, including hormonal prescription oral contraceptives, contraceptive
                       injections, contraceptive patch, intrauterine device, double-barrier method
                       [(e.g., condoms, diaphragm, or cervical cap, with spermicidal foam, cream,
                       or gel)], or male partner sterilization, consistent with local regulations
                       regarding use of birth control methods for subjects participating in
                       clinical studies, for the duration of their participation in the study, or

                    -  Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
                       ligation, or otherwise be incapable of pregnancy), or

                    -  Not heterosexually active

        Exclusion Criteria:

          -  Subject has a very high bleeding risk: Any condition that, in the opinion of the
             investigator, contraindicates anticoagulant therapy or would have an unacceptable risk
             of bleeding, such as, but not limited to, the following:

               -  Any bleeding (defined as bleeding requiring hospitalization, transfusion,
                  surgical intervention, invasive procedures, occurring in a critical anatomical
                  site, or causing disability) within 1 months prior to randomization or occurring
                  during index hospitalization.

               -  Major surgery, biopsy of a parenchymal organ, ophthalmic surgery (excluding
                  cataract surgery), or serious trauma (including head trauma) within 4 weeks
                  before randomization.

               -  A history of hemorrhagic stroke or any intracranial bleeding at any time in the
                  past, evidence of primary intracranial hemorrhage on CT or magnetic resonance
                  imaging scan of the brain, or clinical presentation consistent with intracranial
                  hemorrhage. This applies as well to subjects hospitalized for ischemic stroke
                  upon randomization.

               -  Subject has a history of or current intracranial neoplasm (benign or malignant),
                  cerebral metastases, arteriovenous (AV) malformation, or aneurysm.

               -  Active gastroduodenal ulcer, defined as diagnosed within 1 months or currently
                  symptomatic or known AV malformations of the gastrointestinal tract.

               -  Platelet count &lt;90,000/μl at screening.

               -  Patients with the diagnosis of bronchiectasis, that due to the investigator
                  judgement are at an increased bleeding risk.

          -  Subject has any of the following diseases in the medical history:

               -  Active cancer (excluding non-melanoma skin cancer) defined as cancer not in
                  remission or requiring active chemotherapy or adjunctive therapies such as
                  immunotherapy or radiotherapy. Chronic hormonal therapy (e.g. tamoxifen,
                  anastrozole, leuprolide acetate) for cancer in remission is allowed.

               -  Any medical condition (e.g. atrial fibrillation) that requires use of any
                  therapeutic parenteral or oral anticoagulant(s) (e.g. warfarin sodium or other
                  vitamin K antagonists, Factor IIa or FXa inhibitors, fibrinolytics) concomitantly
                  with study medication.

               -  Subject has known allergies, hypersensitivity, or intolerance to rivaroxaban or
                  any of its excipients.

               -  Baseline eGFR &lt;30 mL/min/1.73m2 calculated using CKD-EPI formula

               -  Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis,
                  cirrhosis) which is associated with coagulopathy or moderate or severe hepatic
                  impairment.

               -  Known HIV infection.

          -  Subject has undergone any of the following procedures or received any of the following
             drugs:

               -  Received fibrinolysis during index hospitalization.

               -  Use of antiplatelet therapy with prasugrel or ticagrelor up to 7 days prior to
                  randomization. Other P2Y12 antagonists can be given. However, the use of
                  concomitant antiplatelet therapy should be carefully considered. ASS &gt; 100 mg/d
                  and continuous NSAIDs should be avoided.

               -  Use of dual antiplatelet therapy, such as aspirin plus clopidogrel during the
                  study.

          -  Subject is a woman who is pregnant or breast-feeding.

          -  Known intolerance or history of hypersensitivity to the active substance or to any of
             the excipients of the Investigational Medicinal Product (IMP)

          -  Subjects who are legally detained in an official institution.

          -  Subjects who may be dependent on the sponsor, the investigator or the trial sites, are
             not eligible to enter the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Landmesser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Co-PI: Andreas M. Zeiher, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe-University, Frankfurt am Main, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Co-PI: Steffen Massberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Co-PI: Ursula Rauch-Kröhnert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulf Landmesser, Prof. Dr.</last_name>
    <phone>+49 30 450 513 702</phone>
    <email>ulf.landmesser@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ursula Rauch-Kroehnert, Prof. Dr. med.</last_name>
    <phone>+49 30 450 513 794</phone>
    <email>ursula.rauch@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kardiologie und Angiologie I Universitätsherzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Dennis Wolf, PD Dr.</last_name>
      <phone>+49 761 270 35460</phone>
      <email>dennis.wolf@universitaets-herzzentrum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Gastroenterology, Infectology and Poisoning Universitäsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Uta Merle, Prof. Dr.</last_name>
      <phone>+49 6221 56-8705</phone>
      <email>uta.merle@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology and Pneumology Clinic Klinikum Garmisch-Partenkirchen</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <state>Bayern</state>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans-Christian Mochmann, Dr.</last_name>
      <phone>+49 8821 77-15 40</phone>
      <email>Hans-Christian.Mochmann@klinikum-gap.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Clinic and Polyclinic I. L. Ludwigs-Maximilians-University Clinic, Munich</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Steffen Massberg, Prof. Dr.</last_name>
      <phone>+49 89 4400-72371</phone>
      <email>Direktion-Med1@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology, Pneumology and Intensive Care Clinic, München Klinik Neuperlach</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jakob Ledwoch, Dr.</last_name>
      <email>jakobledwoch@yahoo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Cardiology Klinik Henningsdorf. Oberhavel Kliniken</name>
      <address>
        <city>Hennigsdorf</city>
        <state>Brandenburg</state>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans-Heinrich Minden, Dr.</last_name>
      <phone>+49 3302 545-4251</phone>
      <email>minden@remove-this.oberhavel-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Cardiology, Angiology und Nephrology Universitätsklinikum Frankfurt, Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Zeiher, Prof. Dr.</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>5789 / 5748</phone_ext>
      <email>zeiher@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic and Polyclinic Internal Medicine Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Felix, Prof. Dr.</last_name>
      <phone>+49 3834 86-80500</phone>
      <email>Felix@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology and Pneumology Clinic Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tim Seidler, Prof. Dr. med.</last_name>
      <phone>+49 551 3963907</phone>
      <email>michaela.jakobeit@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Cardiology and Intensive Care - Klinikum Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Stellbrink, Prof. Dr.</last_name>
      <phone>+49 521 581 3401</phone>
      <email>christoph.stellbrink@klinikumbielefeld.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Clinic I. Marien Hospital, Universitätsklinikum der Ruhr Universität Bochum, Herne</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Timm Westhoff, Prof. Dr.</last_name>
      <phone>+49 2323 499-1671</phone>
      <email>&quot;innere-medizin@marienhospital-herne.de&quot;</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumology, Allergology, Sleep-and Respiratory Medicine Clinic Helios Universitätsklinikum Wupperthal</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Kurt Rasche, Prof. Dr.</last_name>
      <phone>+49 202 896-3902</phone>
      <email>kurt.rasche@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Cardiology, University Medicine Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Münzel, Prof. Dr.</last_name>
      <phone>+49 6113 117-7251</phone>
      <email>tmuenzel@uni-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Vascular Medicine, Städtisches Krankenhaus Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian Schellong, Prof. Dr.</last_name>
      <phone>+49 3514 801 120</phone>
      <email>sebastian.schellong@klinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Clinic I. Universitätsklinikum Carl Gustav Carus, Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jan Beyer-Westenhoff, PD Dr.</last_name>
      <phone>+49 351 458-0</phone>
      <email>jan.beyer@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology, Pneumology and Intensive Care Clinic Helios Klinikum Pirna, Dresden</name>
      <address>
        <city>Pirna</city>
        <state>Sachsen</state>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Steffen Schön, Prof. Dr.</last_name>
      <phone>+49 3501 71 18</phone>
      <phone_ext>-50 41/ -52 11</phone_ext>
      <email>Steffen.Schoen@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Clinic II, University Clinic Schleswig-Holstein - Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ingo Eitel, Prof. Dr.</last_name>
      <phone>+49 451 500 44501</phone>
      <email>ingo.eitel@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology and Infectology Charité University Medicine Berlin, Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Witzenrath, Prof. Dr.</last_name>
      <phone>+49 30 450 653876</phone>
      <email>martin.witzenrath@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine II, Cardiology, Sana Klinikum, Lichtenberg. Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Olaf Göing, Dr.</last_name>
      <phone>+49 30 5518-2129</phone>
      <email>Olaf.Goeing@sana-kl.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Clinic II. St. Joseph Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christiane Erley, Prof. Dr.</last_name>
      <phone>+49 30 7882 2379</phone>
      <email>nephrologie@sjk.de</email>
    </contact>
    <contact_backup>
      <last_name>Jan Cornely</last_name>
      <phone>+ 49 30 7882 2379</phone>
      <email>jan.cornely@sjk.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology Charité University Medicine Berlin, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ulf Landmesser, Prof. Dr.</last_name>
      <phone>+49 30 450 513702</phone>
      <email>ulf.landmesser@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine, Hospital Bethel Berlin in Lichterfelde</name>
      <address>
        <city>Berlin</city>
        <zip>12207</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Aviva Raatz, Dr.</last_name>
      <phone>+49 30 7791 - 2217</phone>
      <email>KHBE@BethelNet.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine/Cardiology department Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Leonhard Bruch, Dr.</last_name>
      <phone>+49 30 5681-3601</phone>
      <email>leonhard.bruch@ukb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology Charité University Medicine Berlin, Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Burkhard Pieske, Prof. Dr.</last_name>
      <phone>+49 30 450 553702</phone>
      <email>burkert.pieske@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine, Cardiology and Intensive Care Clinic Vivantes Humboldt Klinikum, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Steffen Behrens, Prof. Dr.</last_name>
      <phone>+49 30 130 -132651</phone>
      <email>steffen.behrens@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care and Cardiology, Hospital Havelhöhe</name>
      <address>
        <city>Berlin</city>
        <zip>14089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrizio Esposito, Dr.</last_name>
      <phone>+49 30 36501-414</phone>
      <email>fabrizio.esposito@havelhoehe.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Deparment Hospital Waldfriede, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Carsten Büning, Prof. Dr.</last_name>
      <phone>+49 30/81 810 8243</phone>
      <email>innere@waldfriede.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Ulf Landmesser</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>therapeutic anticoagulation</keyword>
  <keyword>thromboprophylaxis</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>standard of care</keyword>
  <keyword>prevention</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>deep venous thrombosis</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>arterial thromboembolism</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>non-hemorrhagic stroke</keyword>
  <keyword>all-cause mortality</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>after protection period</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

